Flow cytometric determination of Src phosphorylation in pediatric patients treated with dasatinib

Pediatric Blood and Cancer

Volumn 53, Issue 6, 2009, Pages 1132-1135

  Guerrouahen, Bella S ^a,b   Wieder, Eric ^a,c   Blanchard, Elisabeth G ^a   Lee, Francis Y ^d   Aplenc, Richard ^e   Corey, Seth J ^a,f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Dasatinib; Phase I; Src kinases; Tyrosine kinase inhibitor

Indexed keywords

DASATINIB; PROTEIN TYROSINE KINASE;

ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG EFFICACY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; STAINING; TREATMENT DURATION;

CHILD; FLOW CYTOMETRY; HUMANS; METHODS; PHOSPHORYLATION; PYRIMIDINES; SRC-FAMILY KINASES; THIAZOLES;

EID: 71049119067     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22083     Document Type: Article

References (10)

1. Baselga J. Targeting tyrosine kinases in cancer: The second wave. Science 2006;312:1175-1178. (Pubitemid 43801135)
2. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-187. (Pubitemid 41058349)
3. Sausville EA, Elsayed Y, Monga M, et al. Signal transduction - Directed cancer treatments. Annu Rev Pharmacol Toxicol 2003;43: 199-231. (Pubitemid 37372640)
4. Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008;111:3941-3967.
5. Irish JM, Kotecha N, Nolan GP. Mapping normal and cancer cell signalling networks: Towards single-cell proteomics. Nat Rev Cancer 2006;6:146-155. (Pubitemid 43361547)
6. Kantarjian H, Jabbour E, Grimley J, et al. Dasatinib. Nat Rev Drug Discov 2006;5:717-718.
7. Le Tourneau C, Faivre S, Raymond E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treat Rev 2008;34:37-48. (Pubitemid 351168610)
8. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:1198-1206. (Pubitemid 351555544)
9. Luo FR, Barrett YC, Yang Z, et al. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCELtrade mark), a multi-targeted kinase inhibitor. Cancer Chemother Pharmacol 2008;62:1065-1074.
10. Dos Santos C, Demur C, Bardet V, et al. A critical role for Lyn in acute myeloid leukemia. Blood 2007;111:2269-2279.